Christian Rolfo, MD
Medical Oncology · Columbus, OHNPI 1134616873
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $140,522 of the $227,386 with a category attached, or 61.8%. It is spread thinly across 36 manufacturers, the largest accounting for just 21.2%. Reporting peaked in 2022 at $54,598 and has fallen 69.8% since, to $16,504 in 2025. Among medical oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1263.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$48K
- Astrazeneca UK Limited$27K
- Regeneron$14K
- Merck Kgaa$13K
- F. Hoffmann-la Roche AG$12K
- Hikma Pharmaceuticals USA$12K
- plus $101K from 30 others
Across 145 payments — averaging $24,474 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2M
- AstraZeneca$526K
- Pfizer$375K
- Merck$267K
- Eli Lilly$116K
- EMD Serono, Inc.$72K
- plus $241K from 8 others
What the payments were for
- Consulting fees$140,52262%
- Speaking & faculty fees$49,11122%
- Grants$1,0940%
- Travel & lodging$29,07413%
- Food & beverage$6,5253%
- Education$1,0600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $48,170 |
| Astrazeneca UK Limited | 12 | $27,064 |
| Regeneron | 17 | $14,361 |
| Merck Kgaa | 3 | $12,750 |
| F. Hoffmann-la Roche AG | 8 | $12,420 |
| Hikma Pharmaceuticals USA | 3 | $11,710 |
| EMD Serono, Inc. | 11 | $11,707 |
| AstraZeneca | 23 | $10,458 |
| Novartis | 7 | $8,692 |
| Janssen Scientific Affairs, LLC | 7 | $8,496 |
| Novocure Inc. | 7 | $6,877 |
| AbbVie | 5 | $6,788 |
| Sanofi-aventis U.S. LLC | 1 | $5,299 |
| Bayer | 5 | $4,740 |
| Daiichi Sankyo Inc. | 8 | $3,895 |
| Amgen | 2 | $3,894 |
| Sanofi | 2 | $3,710 |
| Roche Molecular Systems, Inc. | 6 | $3,568 |
| Jazz Pharmaceuticals Inc. | 2 | $3,275 |
| Genentech USA, Inc. | 6 | $2,674 |
| Boehringer Ingelheim International GmbH | 1 | $2,590 |
| Roche Sequencing Solutions, Inc. | 1 | $2,100 |
| Life Technologies Corporation | 1 | $2,000 |
| Eisai Inc. | 1 | $1,875 |
| Eli Lilly | 1 | $1,800 |
| Boehringer Ingelheim | 5 | $1,725 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,500 |
| Regeneron Healthcare Solutions, Inc. | 7 | $1,393 |
| Blueprint Medicines Corporation | 1 | $1,188 |
| Coherus Oncology, Inc. | 1 | $134 |
| GSK | 1 | $127 |
| Genentech, Inc. | 1 | $124 |
| G1 Therapeutics, Inc. | 1 | $118 |
| Novocure GmbH | 1 | $100 |
| Mirati Therapeutics, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$227,386 in reported general payments places this provider in the 95th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Erlotinib Hcl | 18 | $5,733 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Columbus
- David CarboneColumbus$438K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Timothy BurnsColumbus$64K
- Kai HeColumbus$49K
- Gregory OttersonColumbus$49K
- Sagar SardesaiColumbus$45K
- Asrar AlahmadiColumbus$36K
- John HaysColumbus$35K
- Claire VerschraegenColumbus$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.